Oncotarget

Research Papers:

Single immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer: a systematic review and network metaanalysis of randomized clinical trials using different drugs

PDF  |  Full Text  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:45479-45488. https://doi.org/10.18632/oncotarget.9991

Metrics: PDF 3829 views  |  Full Text 4990 views

Minyong Kang1, Chang Wook Jeong1, Cheol Kwak1, Hyeon Hoe Kim1, Ja Hyeon Ku1

1Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea

Correspondence to:

Ja Hyeon Ku, email: [email protected]

Keywords: urinary bladder neoplasm, chemotherapy, drug therapy, single instillation, systematic review

Received: March 18, 2016     Accepted: May 29, 2016     Published: June 14, 2016

ABSTRACT

We performed a network meta-analysis of randomized controlled trials (RCTs) to compare the efficacy of several intravesical chemotherapeutic (IVC) agents after transurethral resection of bladder tumor (TURB) in non-muscle invasive bladder cancer patients. The literature search was conducted using the Embase, Scopus and PubMed databases for RCTs, including patients with single or multiple, primary or recurrent stage Ta or T1 urothelial carcinoma of the bladder managed with a single, immediate instillation of IVC after TURB. Thirteen RCTs met the eligibility criteria. Pair-wise meta-analysis (direct comparison) showed that pirarubicin [hazard ratio (HR): 0.31], epirubicin (HR: 0.62), and MMC (HR: 0.40) were the most effective drugs for reducing tumor recurrence. Bayesian network meta-analysis (indirect comparison) revealed that treatment with pirarubicin (HR: 0.31), MMC (HR: 0.44), or epirubicin (HR: 0.60) was associated with prolonged recurrence-free survival. Among the drugs examined, only pirarubicin reduced disease progression compared to controls. These results suggest that a single, immediate administration of IVC with pirarubicin, MMC, or epirubicin is associated with prolonged recurrence-free survival following TURB in non-muscle invasive bladder cancer patients, though only pirarubicin also reduced disease progression.